Track Fortress Biotech, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Fortress Biotech, Inc. FBIOP · Stock Open Fortress Biotech, Inc. in new tab

17.27 USD
EPS
-0.86
P/B
3.68
ROE
115.99
Beta
1.19
Loading chart...
Key Metrics
Earnings dateNov. 16, 2026
EPS-0.86
Book Value4.93
Price to Book3.68
Debt/Equity25.87
Growth
Revenue Growth0.14%

DCF Valuation

Tweak assumptions to recompute fair value for Fortress Biotech, Inc. (FBIOP)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Fortress Biotech, Inc. Logo Fortress Biotech, Inc. Analysis (FBIOP)

United States Health Care Official Website Stock

Is Fortress Biotech, Inc. a good investment? Fortress Biotech, Inc. (FBIOP) is currently trading at 17.27 USD.

Earnings Schedule: Fortress Biotech, Inc. is expected to release its next earnings report on Nov. 16, 2026.

Investor FAQ

Does Fortress Biotech, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Fortress Biotech, Inc.?

Fortress Biotech, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 16, 2026. The company currently has a trailing EPS of -0.86.

Company Profile

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Exchange Ticker
NMS (United States) FBIOP
FRA (Germany) CNB0.F
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
2024
1.17 USD
June 30, 2024 0.1950
May 31, 2024 0.1950
April 30, 2024 0.1950
March 31, 2024 0.1950
Feb. 29, 2024 0.1950
Jan. 31, 2024 0.1950
2023
2.34 USD
Dec. 31, 2023 0.1950
Nov. 30, 2023 0.1950
Oct. 31, 2023 0.1950
Sept. 30, 2023 0.1950
Aug. 31, 2023 0.1950
July 31, 2023 0.1950
June 30, 2023 0.1950
May 31, 2023 0.1950
April 30, 2023 0.1950
March 31, 2023 0.1950
Feb. 28, 2023 0.1950
Jan. 31, 2023 0.1950
2022
2.34 USD
Dec. 31, 2022 0.1950
Nov. 30, 2022 0.1950
Oct. 31, 2022 0.1950
Sept. 30, 2022 0.1950
Aug. 31, 2022 0.1950
July 31, 2022 0.1950
June 30, 2022 0.1950
May 31, 2022 0.1950
April 30, 2022 0.1950
March 31, 2022 0.1950
Feb. 28, 2022 0.1950
Jan. 31, 2022 0.1950
2021
2.34 USD
Dec. 31, 2021 0.1950
Nov. 30, 2021 0.1950
Oct. 30, 2021 0.1950
Sept. 30, 2021 0.1950
Aug. 30, 2021 0.1950
July 30, 2021 0.1950
June 30, 2021 0.1950
May 30, 2021 0.1950
April 30, 2021 0.1950
March 31, 2021 0.1950
Feb. 28, 2021 0.1950
Jan. 31, 2021 0.1950
2020
2.34 USD
Dec. 31, 2020 0.1950
Nov. 30, 2020 0.1950
Oct. 31, 2020 0.1950
Sept. 30, 2020 0.1950
Aug. 31, 2020 0.1950
July 31, 2020 0.1950
June 30, 2020 0.5860
March 31, 2020 0.5860
2019
2.34 USD
Dec. 31, 2019 0.5860
Sept. 30, 2019 0.5860
July 1, 2019 0.5860
March 31, 2019 0.5860
2018
2.64 USD
Dec. 31, 2018 0.5860
Sept. 30, 2018 0.5860
June 30, 2018 0.5860
March 30, 2018 0.5860
Jan. 2, 2018 0.2995
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion